Recently, pathogenetic control of diabetic neuropathy has been improved after neurotrophic therapy, such as NGF treatment, and by targeting pathological factors, in both STZ-induced DM animal models and in the human condition [36, 37], which could be relevant to diabetic hearing impairment. The gene discussed is NGF; the disease is diabetic neuropathy.